3-Methoxytyramine accumulation: Effects of typical neuroleptics and various atypical compounds
- 1 October 1986
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie
- Vol. 334 (2) , 125-132
- https://doi.org/10.1007/bf00505811
Abstract
The accumulation of 3-methoxytyramine (3-MT), the O-methylated metabolite of dopamine (DA), in rat striatum was used to assess the effects of drugs on dopaminergic activity. This was accomplished by pretreating rats with pargyline to completely inhibit 3-MT catabolism. Under the conditions used, 3-MT accumulation was linear over time for at least 90 minutes. Apomorphine and γ-butyrolactone, drugs which depress the activity of DA-containing neurons, decreased striatal 3-MT accumulation; whereas typical neuroleptics (haloperidol, fluphenazine, chlorpromazine), which increase the activity of DA-containing neurons, increased striatal 3-MT accumulation. In addition, a number of other drugs which block DA receptors and exert various atypical actions on dopaminergic functioning were examined. These “atypical” compounds (clozapine, buspirone, molindone) also increased striatal 3-MT accumulation, but were generally less potent than the typical neuroleptics examined. Moreover, the potencies of the typical neuroleptics and “atypical” compounds that were tested appear to be somewhat related to their affinities for D-2 DA receptors, as measured by their abilities to displace 3H-spiperone from rat striatal membrane preparations. Interestingly, this relationship was less evident when NaCl was omitted from the 3H-spiperone binding assay buffer. The potential antipsychotic drugs, BW 234U and SCH 23390, were also investigated for their effects on 3-MT accumulation and 3H-spiperone binding, and they were relatively inactive in both of these measures of dopaminergic activity. The observation that SCH 23390, a D-1 DA receptor antagonist, had negligible effects on 3-MT accumulation suggests that D-1 receptor blockade, unlike D-2 blockade, may have minimal effects on DA release. The relevance of the above findings to understanding the effects of drugs on dopaminergic transmission and the advantages of measuring 3-MT accumulation instead of basal 3-MT concentrations are discussed.This publication has 53 references indexed in Scilit:
- Complete Conversion of Brain D2 Dopamine Receptors from the High‐ to the Low‐Affinity State for Dopamine Agonists, Using Sodium Ions and Guanine NucleotideJournal of Neurochemistry, 1985
- SCH23390 causes persistent antidopaminergic effects in vivo: Evidence for longterm occupation of receptorsLife Sciences, 1985
- Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D1 antagonistLife Sciences, 1985
- Open label evaluation of the novel antipsychotic compound BW234U in chronic schizophrenicsDrug Development Research, 1985
- BW234: A nondopamine receptor-blocking antipsychotic drug without extrapyramidal side effects?Drug Development Research, 1984
- Buspirone: A potential atypical neurolepticLife Sciences, 1983
- Enhanced stereotyped response to amphetamine after pretreatment with small doses of molindone☆Neuropharmacology, 1983
- 3-methoxytyramine and different neuroleptics: Dissociation from HVA and DOPACLife Sciences, 1978
- The in Vivo Effect of Tropolone on Noradrenaline Metabolism and Catechol‐O‐Methyl Transferase Activity in Tissues of the RatActa Pharmacologica et Toxicologica, 1973
- Formation of Phenolic Acids in Brain after Administration of 3,4‐DihydroxyphenylalanineActa Physiologica Scandinavica, 1962